Information Provided By: 
Fly News Breaks for September 26, 2016
CHE
Sep 26, 2016 | 07:16 EDT
Oppenheimer analyst Michael Wiederhorn believes Chemed remains an attractive longer-term investment in the rocky healthcare universe, given its strong balance sheet/cash flow profiles, limited exposure to the ACA and a stable reimbursement profile. Further, the analyst expects the company to continue to make the most out of a challenging 2016, while 2017 should represent a return to solid organic growth levels. He reiterates an Outperform rating and $155 price target on the shares.
News For CHE From the Last 2 Days
There are no results for your query CHE
